US 12,102,720 B2
Cleavable lipids
Braydon Charles Guild, Concord, MA (US); Michael Heartlein, Boxborough, MA (US); Frank DeRosa, Chelmsford, MA (US); and Jerry Chi Zhang, Lexington, MA (US)
Assigned to Translate Bio, Inc., Cambridge, MA (US)
Filed by Translate Bio, Inc., Lexington, MA (US)
Filed on Dec. 20, 2021, as Appl. No. 17/556,316.
Application 17/556,316 is a continuation of application No. 16/790,407, filed on Feb. 13, 2020, granted, now 11,234,936.
Application 16/790,407 is a continuation of application No. 16/452,353, filed on Jun. 25, 2019, granted, now 10,702,478, issued on Jul. 7, 2020.
Application 16/452,353 is a continuation of application No. 15/887,693, filed on Feb. 2, 2018, granted, now 10,507,183, issued on Dec. 17, 2019.
Application 15/887,693 is a continuation of application No. 15/651,832, filed on Jul. 17, 2017, abandoned.
Application 15/651,832 is a continuation of application No. 14/124,615, granted, now 9,717,690, issued on Aug. 1, 2017, previously published as PCT/US2012/041663, filed on Jun. 8, 2012.
Claims priority of provisional application 61/494,882, filed on Jun. 8, 2011.
Claims priority of provisional application 61/494,745, filed on Jun. 8, 2011.
Prior Publication US 2022/0202718 A1, Jun. 30, 2022
Int. Cl. A61K 9/19 (2006.01); A61K 9/127 (2006.01); A61K 31/7088 (2006.01); A61K 38/45 (2006.01); A61K 38/46 (2006.01); A61K 38/47 (2006.01); A61K 38/50 (2006.01); C07C 323/25 (2006.01); C07C 323/27 (2006.01); C07C 323/44 (2006.01); C07D 233/64 (2006.01); C07J 41/00 (2006.01); C07J 43/00 (2006.01); C12N 15/88 (2006.01); A61K 9/51 (2006.01)
CPC A61K 9/19 (2013.01) [A61K 9/1271 (2013.01); A61K 9/1272 (2013.01); A61K 31/7088 (2013.01); A61K 38/45 (2013.01); A61K 38/465 (2013.01); A61K 38/47 (2013.01); A61K 38/50 (2013.01); C07C 323/25 (2013.01); C07C 323/27 (2013.01); C07C 323/44 (2013.01); C07D 233/64 (2013.01); C07J 41/0055 (2013.01); C07J 43/003 (2013.01); C12N 15/88 (2013.01); A61K 9/5123 (2013.01); C12Y 201/03003 (2013.01); C12Y 203/01 (2013.01); C12Y 207/08015 (2013.01); C12Y 301/06 (2013.01); C12Y 302/01022 (2013.01); C12Y 302/01035 (2013.01); C12Y 302/01046 (2013.01); C12Y 302/01076 (2013.01); C12Y 305/03001 (2013.01)] 10 Claims
 
1. A lyophilized pharmaceutical composition comprising a lipid nanoparticle and a lyoprotectant that is sucrose,
wherein the lipid nanoparticle comprises:
mRNA;
a cationic lipid,
a PEG-modified lipid that is DMG-PEG2000,
a non-cationic lipid selected from the group consisting of DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DOPE (1,2-dioleyl-sn-glycero-3-phosphoethanolamine), DPPE (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine), DMPE (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine), DOPG (1,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol)), DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine), DLPE (1,2-dilauroyl-sn-glycero-3-phosphoethanolamine), DPPS (1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine), and
a helper lipid that is cholesterol.